2 completed, 2 recruiting, 1 active not recruiting. 2 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Atypical Hyperplasia: new trials by email Literature Review of Atypical Hyperplasia trials Research Report on Atypical Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium Wegovy, Mirena - Endometrial Cancer, Atypical Hyperplasia | Phase 2 | Recruiting | GynOncTrials | 71 | 2026-09-17 | 2026-10-05 |
| Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Bariatric Surgery - Endometrial Cancer, Atypical Hyperplasia | Not applicable | Recruiting | University Health Network, Toronto | 36 | 2021-05-14 | 2025-03-14 |
| Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study - Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2017-11-15 | 2025-08-29 |
| OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer hysteroscopy/curettage in case of suspicious aspect will be done a rapid section - Endometrial Cancer, Atypical Hyperplasia | Completed | Krankenhaus Barmherzige Schwestern Linz | 300 | 2013-05-01 | 2016-08-09 | |
| Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up Tamoxifen, placebo - Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm | Phase 3 | Active not recruiting | Andrea DeCensi | 500 | 2008-11-12 | 2023-07-17 |
Endometrial Neoplasms (4) · Breast Neoplasms (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Endometrial Hyperplasia (1) · Neoplasm Recurrence, Local (1)
Neoplasms (5) · Neoplasms by Site (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Uterine Diseases (4) · Uterine Neoplasms (4) · Adenocarcinoma (1) · Breast Carcinoma In Situ (1) · Breast Diseases (1) · Carcinoma (1)
Bariatric Surgery (1) · Curettage (1) · Hysteroscopy (1) · Levonorgestrel (1) · Pharmacogenomic Variants (1) · Tamoxifen (1) · exemestane (1) · semaglutide (1)
Andrea DeCensi (1) · GynOncTrials (1) · Krankenhaus Barmherzige Schwestern Linz (1) · National Cancer Institute (NCI) (1) · University Health Network, Toronto (1)
Canada (2) · Austria (1) · Italy (1) · United States (1)
Sarah E Ferguson, MD (2) · Andrea DeCensi, MD (1) · Britt K Erickson (1) · Rachel Soyoun Kim, MD (1)
PMID 23106852, PMID 28265757, PMID 30973790, PMID 33608319, PMID 33767162, PMID 36917758, PMID 36971688
N01CN00033 (1), P30CA014520 (1)